Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, ...
MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs
University Of Pennsylvania United States United Kingdom Tammy Groene Elizabeth Bruckheimer Michael Hogarty
Source: eagletribune.com